Amarin Corp Plc (AMRN)

[sharinky]

Per ICER - A consistent treatment benefit was observed for both the primary and key secondary composite endpoints in subgroups with and without diabetes mellitus, with and without renal dysfunction (eGFR<60 vs. ≥60 mL/min/1.732), with and without elevated triglyceride levels (≥150 vs. <150 mg/dL and ≥200 vs. <200 mg/dL), and in subgroups stratified by hsCRP level at baseline (≤2 vs >2 mg/L)

They can't ignore a consistent treatment benefit. There could also be subgroup analysis within the non-diabetics and there is also Anchor.